Additional preclinical data are needed, especially regarding the effect of TNFR2 agonists and antagonists on various human cell types (Tconvs, Tregs, and cancer cells) in vitro, before the start-up of clinical trials evaluating their efficacy and safety for prevention and/or treatment of aGVHD and posttransplant relapse of hematologic disease, respectively. Here, TNFRSF1B is linked to cancer.